Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Extavia

- PMLiVE

Novartis tops leaderboard at PM Society Digital Media Awards

Secures four wins for two separate campaigns

- PMLiVE

Merck Serono puts faith in lung cancer candidate

Continues tecemotide development despite underwhelming phase III results

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

Roche - Basel

Roche’s Kadcyla and Bayer’s Xofigo near EU approval

Cancer drugs receive CHMP backing

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

China flag thumb

Novartis’ Alcon unit diverted trial money for bribes, claims paper

21st Century Business Herald publishes more allegations of corruption in China

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

Bayer symbol

Bayer plans Russian expansion

Eyes growing demand from country's rising middle class

Harnessing social media for campaign success

Digital excellence from Ruder Finn's meningitis work for Novartis

Novartis building

Novartis signs cell therapy deal with Regenerex

Involves platform that could allow transplant patients to live without lifelong immunosuppression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links